Crowded Indian Semaglutide Market
CEO acknowledged semaglutide launch will face intense competition with multiple generic entrants, own-brand launches, out-licensing deals, and Margo's lower-priced variant already gaining traction in India.
NATCOPHARM / bear-case history
Track the concerns that keep returning.
Natco Pharma · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
medium
Pending FDA Classification for Chennai Facility
Chennai formulation plant inspection completed in 2025 with observations described as 'procedural in nature'; classification expected in 30-40 days could impact US formulation export capabilities.
M&A Timeline Vagueness
When pressed on acquisition timeline and specifics, CEO deflected saying 'until it's done, it's not done' without committing to deal size, geography, or vertical, creating execution uncertainty for the ₹2,500 crore cash deployment.
Zero Revlimet Revenue Creates Base Business Volatility
With Revlimid completely absent this quarter (and Q4 not budgeted), the base quarterly revenue of ₹700-750 crore leaves limited margin for error before new product launches contribute in FY27.